**INTRODUCTION**

- **Liverfasc** GP+ (LIVERSTAT) (Fibronostics, Florida, US), an AI-based propriety blood test, was validated against liver biopsy (LB) to identify the presumed NAFLD clinical stages. (Poster 431-SAT)
- **GP+ variables** are common blood biomarkers (lipid panel, liver enzymes, glucose and total bilirubin bilirubin) with patient’s anthropometrics.

**Aims**

The primary aim was to assess retrospectively the **GP+ (LIVERSTAT)** performance and concordance rate (CR) with liver biopsy and Fibroscan as second step after FIB-4 for the assessment of advanced fibrosis (F3F4) in NAFLD patients.

**Methods**

N=176 NAFLD Patients with prospectively collected **GP+ (LIVERSTAT)** have been included from a tertiary hepatology center with biopsy- proven NAFLD and concomitant FIB-4 and liver stiffness measurement (LSM). ALCESE (E) and C-statistics were used to assess the accuracy of each noninvasive test (NIT) against liver biopsy.

**Results**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>n=176</th>
<th>n=85</th>
<th>n=64</th>
<th>n=27</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>57.2</td>
<td>57.2</td>
<td>57.2</td>
<td>57.2</td>
</tr>
<tr>
<td>BMI</td>
<td>31.9</td>
<td>31.9</td>
<td>31.9</td>
<td>31.9</td>
</tr>
<tr>
<td>ALT</td>
<td>32.8</td>
<td>32.8</td>
<td>32.8</td>
<td>32.8</td>
</tr>
<tr>
<td>Glucose</td>
<td>107.1</td>
<td>107.1</td>
<td>107.1</td>
<td>107.1</td>
</tr>
</tbody>
</table>

**Characteristics of Included Patients**

<table>
<thead>
<tr>
<th>NITS</th>
<th>G-P+ FIB 4</th>
<th>LSM FIB 4</th>
<th>F4 FIB 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.3</td>
<td>71%</td>
<td>31%</td>
<td>17%</td>
</tr>
<tr>
<td>1.3</td>
<td>63%</td>
<td>28%</td>
<td>53%</td>
</tr>
<tr>
<td>2.68</td>
<td>68%</td>
<td>100%</td>
<td>58%</td>
</tr>
</tbody>
</table>

**FIB-4 cut-offs to rule-in and rule-out advanced fibrosis F3F4**

- **FIB-4 < 1.3** GRAY ZONE
- **FIB-4 ≥ 2.68**

**GP+ (LIVERSTAT)** has been trained and validated against histopathological classification to identify the presumed AFLD clinical classes:

- **Class 0** No presumed fibrosis/steatosis
- **Class 1** Presumed steatosis only
- **Class 2** Presumed fibrosis, not advanced
- **Class 3** Presumed advanced fibrosis

**Conclusions**

**GP+ (LIVERSTAT)**, is readily available and can be used to identify F3-F4 as a second step in patients with indeterminate FIB-4.

**References**

1. [https://www.fibronostics.com/](https://www.fibronostics.com/)

**Contact Information**

naimalkhouri@liver.com

**Disclosures**

MM - Fibronostics